secwatch.observer — SEC 8-K summary
======================================

Issuer:     Larimar Therapeutics, Inc. (LRMR)
CIK:        0001374690
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-065186
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Larimar Therapeutics receives FDA Breakthrough Therapy Designation for nomlabofusp in Friedreich's ataxia
--------------------------------------------------------------------------------

- FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia.
- FDA aligned on using skin FXN as a surrogate endpoint to support BLA seeking accelerated approval.
- Planned BLA submission remains on track for June 2026; topline open-label data expected Q2 2026.
- Global confirmatory Phase 3 study to initiate Q2 2026; first patient dosing targeted mid-2026.
- U.S. launch targeted for first-half 2027, if approved; estimated 5,000 U.S. patients with FA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/0001193125-26-065186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1374690/000119312526065186/lrmr-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-065186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer